4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で311.18%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 85.21Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 85.21Mです。
適正水準
同社の最新のPEは-5.06で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は54.90M株で、前四半期比で5.97%減少しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.34です。